Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive , carbapenem-resistant (CRE), and nonfermenting Gram-negative bacilli, including , , and species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE No comparators were active against multidrug-resistant isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against isolates. Overall, cefiderocol was associated with the lowest level of resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179642 | PMC |
| http://dx.doi.org/10.1128/AAC.01955-19 | DOI Listing |
Publication Analysis
Top Keywords
isolates cancer
8
cancer patients
8
appreciable activity
8
isolates
5
activity
4
activity cefiderocol
4
cefiderocol comparators
4
comparators isolates
4
patients cefiderocol
4
cefiderocol inhibited
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!